ArticleWorld journal of methodology2026
High red cell distribution width as a prognostic indicator in heart failure.
Article in World journal of methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRed cell distribution width (RDW) measures the red blood cell size variation. Elevated RDW has been associated with various adverse health outcomes, including cardiovascular diseases.
aimTo analyze current evidence on the prognostic significance of high RDW in patients with heart failure (HF).
methodsA comprehensive literature search was conducted across multiple databases, including PubMed, EMBASE, and Google Scholar, up to May 2024. Studies were included if they investigated the relationship between RDW levels and outcomes in HF patients. Compared to those in the lowest quartile. The primary outcome was all-cause mortality. Compared to those in the lowest quartile. Heterogeneity was assessed using the
resultsSeven studies, including a total of 11460 HF patients, were analyzed. The participants' mean age varied between 60 years and 80 years, with 6562 (57.26%) in the lower quartile. Patients in the highest quartile of RDW (> 15.21%) had a significantly increased risk of all-cause mortality, with an odds ratio of 1.84 (95%CI: 1.31-2.57,
conclusionThis meta-analysis confirms that high RDW is a robust predictor of adverse outcomes in patients with HF, highlighting its potential utility as a simple, cost-effective biomarker for risk stratification. Future research should focus on elucidating the mechanisms underlying this association and exploring the potential benefits of RDW-guided therapeutic strategies in HF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.